Interstitial Lung Disease
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Interstitial Lung Disease is a moderately active landscape with 68 programs across 32 companies. The most active players are Sclnow Biotechnology Co., Ltd., Bayer, Bristol-Myers Squibb. 9 therapies are approved with 11 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
88%
Small molecule
70 of 80 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 80 classified programs, each share of the total. Modality classified for 99% of 86 pipeline programs.
Analysis
Trial Status
101
clinical trials
Clinical Trials
Trial Activity
101 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)